Indian Journal of Physical Medicine and Rehabilitation

Register      Login

VOLUME 23 , ISSUE 3 ( September, 2012 ) > List of Articles

RESEARCH ARTICLE

Audit of Safety of Intramuscular Botulinum Toxin Injections among Patients Receiving Warfarin Anticoagulation Therapy

Yogendra Jagatsinh, Jim George

Citation Information : Jagatsinh Y, George J. Audit of Safety of Intramuscular Botulinum Toxin Injections among Patients Receiving Warfarin Anticoagulation Therapy. Indian J Phy Med Rehab 2012; 23 (3):101-104.

DOI: 10.5005/ijopmr-23-3-101

Published Online: 00-09-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background

Botulinum toxin (BTX) intramuscular injections are an effective treatment for spasticity in acquired brain injury. Despite use since the 1980s, issues concerning technique, dose and long-term side-effects remain unresolved. For example, the safety of BTX in warfarinised patients is unclear. There are two studies reporting the risk of intramuscular injections in patients receiving anticoagulant therapy with regard to possible local haematoma formation. There is no advice on this subject in the manufacturers’ summary of product characteristics for the original brand of warfarin, Dysport, BOTOX, Xeomin or in the British National Formulary.

Aim

To assess the safety of BTX injections in patients receiving oral anticoagulation.

Design

Prospective audit of safe practice.

Setting

Outpatient setting in a rehabilitation centre.

Population

Adult population affected with spasticity with acquired brain injury and receiving concurrent warfarin anticoagulant therapy.

Methods

Fourteen patients who were receiving anticoagulant therapy were given regular BTX (number of injection cycles or total mean no of injections each). Patients gave written informed consent before the injections. Injection technique did not differ from that used for un-anticoagulated patients. Patients were assessed by the injector for obvious haemorrhage in the first 15 minutes after the injection resulting in swelling, bruising, tenderness or haematoma. Patients were asked to watch for appearance of local reactions like swelling, bruising or haematoma and pain in the first week.

Results

There were no clinically detectable local complications after intramuscular injections and no major or minor bleeding episodes after BTX injections.

Conclusion

In our group, BTX injections were administered intramuscularly to patients who were receiving anticoagulant therapy without significant risk of local bleeding. However, injections must be used with caution in patients with an INR above the therapeutic range.

Clinical rehabilitation impact

BTX can be safely given in patients on anticoagulation therapy with safety checks in place.


PDF Share
  1. American Hospital Formulary service-Drug information. USA (Bethesda): American Society of Health-System Pharmacists, 2005; 1416.
  2. Can intramuscular injections be given to patients taking warfarin? Quality Assurance. Southampton University Hospitals Trust.
  3. Goldshield Pharmaceuticals. June 2003.
  4. Thrombosis and anti-thrombotic therapy. In Wintrobe's Clinical Hematology 9th ed; Vol 2: 1533.
  5. The use of thrombolytic agents; choice of patient, drug administration, lab monitoring. Ann Intern Med 1979;90:802.
  6. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy. Arch Intern Med 1995;155:1529-31.
  7. Influenza vaccination and warfarin anticoagulation: a comparison of subcutaneous and intramuscular routes of administration in elderly men. Pharmacotherapy 1998;18:631-6.
  8. Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: single blinded multi-centre randomized controlled trial. BMC Blood Disorders 2008; 8: 1-7.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.